［欧文原著］
1. Takamori M, Takahashi M, Yasukawa Y, Iwasa K, Nemoto Y, Suenaga A, Nagataki S, Nakamura T: Antibodies to recombinant synaptotagmin and calcium channel subtypes in Lambert-Eaton myasthenic syndrome. Journal of the neurological sciences 133:95-101. 1995
2. Iwasa K: Striational autoantibodies in myasthenia gravis mainly react with ryanodine receptor. Muscle & nerve 20:753-756. 1997
3. Yoshikawa H, Iwasa K, Satoh K, Takamori M: FK506 prevents induction of rat experimental autoimmune myasthenia gravis. Journal of autoimmunity 10:11-16. 1997
4. Takamori M, Iwasa K, Komai K Antibodies to synthetic peptides of the alpha1A subunit of the voltage-gated calcium channel in Lambert-Eaton myasthenic syndrome. Neurology 48:1261-1265. 1997
5. Iwasa K, Komai K, Takamori M: Spontaneous thymoma rat as a model for myasthenic weakness caused by anti-ryanodine receptor antibodies. Muscle & nerve 21:1655-1660. 1998
6. Iwasa K, Nakajima K, Yoshikawa H, Tada A, Taki J, Takamori M: Decreased myocardial 123I-MIBG uptake in Parkinson’s disease. Acta neurologica Scandinavica 97:303-306. 1998
7. Komai K, Iwasa K, Takamori M: Calcium channel peptide can cause an autoimmune-mediated model of Lambert-Eaton myasthenic syndrome in rats. Journal of the neurological sciences 166:126-130. 1999
8. Takamori M, Komai K, Iwasa K: Antibodies to calcium channel and synaptotagmin in Lambert-Eaton myasthenic syndrome. The American journal of the medical sciences 319:204-208. 2000
9. Iwasa K, Takamori M, Komai K, Mori Y: Recombinant calcium channel is recognized by Lambert-Eaton myasthenic syndrome antibodies. Neurology 54:757-759. 2000
10. Pinto A, Iwasa K, Newland C, Newsom-Davis J, Lang B: The action of Lambert-Eaton myasthenic syndrome immunoglobulin G on cloned human voltage-gated calcium channels. Muscle & nerve 25:715-724. 2002
11. Yasukawa Y, Yoshikawa H, Iwasa K, Yamada M, Takamori M: Comparative study of pre-operative thymic imaging and pathology in patients with myasthenia gravis. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 11:610-613. 2004
12. Noguchi M, Yoshita M, Matsumoto Y, Ono K, Iwasa K, Yamada M: Decreased beta-amyloid peptide42 in cerebrospinal fluid of patients with progressive supranuclear palsy and corticobasal degeneration. Journal of the neurological sciences 237:61-65. 2005
13. Ono K, Noguchi M, Matsumoto Y, Yanase D, Iwasa K, Naiki H, Yamada M: Cerebrospinal fluid of Alzheimer patients promotes beta-amyloid fibril formation in vitro. Neurobiology of disease 20:233-240. 2005
14. Yoshikawa H, Sato K, Edahiro S, Furukawa Y, Maruta T, Iwasa K, Watanabe H, Takaoka S, Suzuki Y, Takamori M, Yamada M: Elevation of IL-12 p40 and its antibody in myasthenia gravis with thymoma. Journal of neuroimmunology 175:169-175. 2006
15. Ono K, Noguchi-Shinohara M, Samuraki M, Matsumoto Y, Yanase D, Iwasa K, Naiki H, Yamada M: Blood-borne factors inhibit Alzheimer’s beta-amyloid fibril formation in vitro. Experimental neurology 202:125-132. 2006
16. Hamaguchi T, Iwasa K, Okino S, Yamada M: Carotid duplex ultrasonography during head-up tilt in patients with orthostatic hypotension. European neurology 57:219-222. 2007
17. Furukawa Y, Yoshikawa H, Iwasa K, Yamada M: Clinical efficacy and cytokine network-modulating effects of tacrolimus in myasthenia gravis. Journal of neuroimmunology 195:108-115. 2008
18. Maruta T, Yoshikawa H, Fukasawa S, Umeshita S, Inaoka Y, Edahiro S, Kado H, Motozaki Y, Iwasa K, Yamada M: Autoantibody to dihydropyridine receptor in myasthenia gravis. Journal of neuroimmunology 208:125-129. 2009
19. Shibata-Hamaguchi A, Ishida C, Iwasa K, Yamada M: Prevalence of spinocerebellar degenerations in the Hokuriku district in Japan. Neuroepidemiology 32:176-183. 2009
20. Iwasa K, Kato-Motozaki Y, Furukawa Y, Maruta T, Ishida C, Yoshikawa H, Yamada M: Up-regulation of MHC class I and class II in the skeletal muscles of myasthenia gravis. Journal of neuroimmunology 225:171-174. 2010
21. Morinaga A, Ono K, Ikeda T, Ikeda Y, Shima K, Noguchi-Shinohara M, Samuraki M, Yanase D, Yoshita M, Iwasa K, Mastunari I, Yamada M: A comparison of the diagnostic sensitivity of MRI, CBF-SPECT, FDG-PET and cerebrospinal fluid biomarkers for detecting Alzheimer’s disease in a memory clinic. Dementia and geriatric cognitive disorders 30:285-292. 2010
22. Suzuki S, Utsugisawa K, Iwasa K, Satoh T, Nagane Y, Yoshikawa H, Kuwana M, Suzuki N: Autoimmunity to endoplasmic reticulum chaperone GRP94 in myasthenia gravis. Journal of neuroimmunology 237:87-92. 2011
23. Sugano K, Yokogawa M, Yuki S, Dohmoto C, Yoshita M, Hamaguchi T, Yanase D, Iwasa K, Komai K, Yamada M: Effect of cognitive and aerobic training intervention on older adults with mild or no cognitive impairment: a derivative study of the nakajima project. Dementia and geriatric cognitive disorders extra 2:69-80. 2012
24. Takahashi R, Ono K, Ikeda T, Akagi A, Noto D, Nozaki I, Sakai K, Asakura H, Iwasa K, Yamada M: Coagulation and fibrinolysis abnormalities in familial amyloid polyneuropathy. Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis 19:129-132. 2012
25. Kobayashi S, Yokoyama S, Maruta T, Negami M, Muroyama A, Mitsumoto Y, Iwasa K, Yamada M, Yoshikawa H: Autoantibody-induced internalization of nicotinic acetylcholine receptor alpha3 subunit exogenously expressed in human embryonic kidney cells. Journal of neuroimmunology 257：102-106.2013
26. Noguchi-Shinohara M, Yuki S, Dohmoto C, Ikeda Y, Samuraki M, Iwasa K, Yokogawa M, Asai K, Komai K, Nakamura H, Yamada M. Differences in the prevalence of dementia and mild cognitive impairment and cognitive functions between early and delayed responders in a community-based study of the elderly. J Alzheimers Dis. 2013;37(4):691-8.
27. Takahashi R, Ono K, Shibata S, Nakamura K, Komatsu J, Ikeda Y, Ikeda T, Samuraki M, Sakai K, Iwasa K, Kayano D, Yamada M. Efficacy of diflunisal on autonomic dysfunction of late-onset familial amyloid polyneuropathy (TTR Val30Met) in a Japanese endemic area. J Neurol Sci.345(1-2):231-5.2014
28. Iwasa K, Yoshikawa H, Samuraki M, Shinohara M, Hamaguchi T, Ono K, Nakamura H, Yamada M. Myasthenia gravis: predictive factors associated with the synchronized elevation of anti-acetylcholine receptor antibody titer in Kanazawa, Japan. J Neuroimmunol. 15;267(1-2):97-101. 2014
29. Noguchi-Shinohara M, Yuki S, Dohmoto C, Ikeda Y, Samuraki M, Iwasa K, Yokogawa M, Asai K, Komai K, Nakamura H, Yamada M. Consumption of green tea, but not black tea or coffee, is associated with reduced risk of cognitive decline. PLoS One. 14;9(5):e96013. 2014
30. Iwasa K, Nambu Y, Motozaki Y, Furukawa Y, Yoshikawa H, Yamada M. Increased skeletal muscle expression of the endoplasmic reticulum chaperone GRP78 in patients with myasthenia gravis. J Neuroimmunol. 2014 Aug 15;273(1-2):72-6.
31. Ishida C, Kobayashi K, Kitamura T, Ujike H, Iwasa K, Yamada M. Frontotemporal dementia with parkinsonism linked to chromosome 17 with the MAPT?R406W mutation presenting with a broad distribution of abundant senile plaques. Neuropathology. 2015 Feb;35(1):75-82.
32. Sakai K, Ikeda Y, Ishida C, Matsumoto Y, Ono K, Iwasa K, Yamada M. Inclusion body myositis with granuloma formation in muscle tissue. Neuromuscul Disord. 2015;25(9):706-12.
33. Noguchi-Shinohara M, Ono K, Hamaguchi T, Iwasa K, Nagai T, Kobayashi S, Nakamura H, Yamada M. Pharmacokinetics, Safety and Tolerability of Melissa officinalis Extract which Contained Rosmarinic Acid in Healthy Individuals: A Randomized Controlled Trial. PLoS One. 2015;10(5):e0126422.
34. Iwasa K, Furukawa Y, Yoshikawa H, Yamada M. Caveolin-3 is aberrantly expressed in skeletal muscle cells in myasthenia gravis. J Neuroimmunol. 2016;301:30-34.
35. Komatsu J, Sakai K, Nakada M, Iwasa K, Yamada M. Long spinal cord lesions in a patient with pathologically proven multiple sclerosis. J Clin Neurosci. 2017;42:106-108.
36. Nakano H, Sakai K, Iwasa K, Yamada M. Cervical Flexion Myelopathy Eleven Years after a Cervical Spinal Cord Injury. Intern Med. 2017;56(16):2213-2215.
37. Sakai K, Asakawa M, Takahashi R, Ishida C, Nakamura R, Hamaguchi T, Ono K, Iwasa K, Yamada M. Coexistence of transthyretin- and Aβ-type cerebral amyloid angiopathy in a patient with hereditary transthyretin V30M amyloidosis. J Neurol Sci. 2017;381:144-146.
38. Iwasa K, Yoshikawa H, Hamaguchi T, Sakai K, Shinohara-Noguchi M, Samuraki M, Takahashi K, Yanase D, Ono K, Ishida C, Yoshita M, Nakamura H, Yamada M. Time-series analysis: variation of anti-acetylcholine receptor antibody titer in myasthenia gravis is related to incidence of Mycoplasma pneumoniae and influenza virus infections. Neurol Res. 2018;40(2):102-109
39. Yuki-Nozaki S, Noguchi-Shinohara M, Domoto C, Ikeda Y, Samuraki M, Iwasa K, Yokogawa M, Asai K, Komai K, Nakamura H, Yamada M. Differences in Dementia Beliefs between Non-Demented Public Screeners and In-Home Screeners and Their Potential Impact on Future Dementia Screening Intention: The Nakajima Study. J Alzheimers Dis. 2018;62(4):1651-1661.
40. I shimiya M, Nakamura H, Kobayashi Y, Noguchi-Shinohara M, Abe C, Dohmoto C, Ikeda Y, Tokuno K, Ooi K, Yokokawa M, Iwasa K, Komai K, Kawashiri S, Yamada M. Tooth loss-related dietary patterns and cognitive impairment in an elderly Japanese population: The Nakajima study. PLoS One. 2018;15;13(3):e0194504.
41. Noguchi-Shinohara M, Abe C, Yuki-Nozaki S, Dohmoto C, Mori A, Hayashi K, Shibata S, Ikeda Y, Sakai K, Iwasa K, Yokogawa M, Ishimiya M, Nakamura H, Yokoji H, Komai K, Nakamura H, Yamada M. Higher Blood Vitamin C Levels are Associated with Reduction of Apolipoprotein E E4-related Risks of Cognitive Decline in Women: The Nakajima Study. J Alzheimers Dis. 2018;63(4):1289-1297.
42. Iwasa K, Yoshikawa H, Furukawa Y, Yamada M. Programmed cell death ligand 1 expression is upregulated in the skeletal muscle of patients with myasthenia gravis. J Neuroimmunol. 2018;325:74-78.
43.Noguchi-Shinohara M, Hamaguchi T, Sakai K, Komatsu J, Iwasa K, Horimoto M, Nakamura H, Yamada M, Ono K.: Effects of Melissa officinalis Extract Containing Rosmarinic Acid on Cognition in Older Adults Without Dementia: A Randomized Controlled Trial. Journal of Alzheimers Disease, doi: 10.3233/JAD-220953, 2022.12
44.Iwasa K, Furukawa Y, Yoshikawa H, Yamada M, Ono K.: CD59 Expression in Skeletal Muscles and Its Role in Myasthenia Gravis. Neurology Neuroimmunology and Neuroinflammation, 10(1), e200057, doi: 10.1212/NXI.0000000000200057, 2023.1
45.Noguchi-Shinohara M, Ono K, Yuki-Nozaki S, Iwasa K, Yokogawa M, Komai K, Thyreau B, Tatewaki Y, Taki Y, Shibata M, Ohara T, Hata J, Ninomiya T, Yamada M.: Association of the prefrailty with global brain atrophy and white matter lesions among cognitively unimpaired older adults: the Nakajima study. Scientific Reports. 12(1), 12129, doi: 10.1038/s41598-022-16190-7, 2022.8
46.Yoshikawa H, Adachi Y, Nakamura Y, Kuriyama N, Murai H, Nomura Y, Sakai Y, Iwasa K, Furukawa Y, Kuwabara S, Matsui M; Taskforce of Validation of Evidence-based Diagnosis and Guidelines, and Impact on Quality of Life (QOL) in Patients with Neuroimmunological Diseases.: Two-step nationwide epidemiological survey of myasthenia gravis in Japan 2018. PLoS One, 17(9), e0274161, doi: 10.1371/journal.pone.0274161, 2022.9
47.Yoshikawa H, Adachi Y, Nakamura Y, Kuriyama N, Murai H, Nomura Y, Sakai Y, Iwasa K, Furukawa Y, Kuwabara S, Matsui M.: Nationwide survey of Lambert-Eaton myasthenic syndrome in Japan. BMJ Neurology Open, 4(2), e000291, doi: 10.1136/bmjno-2022-000291. 2022.9
48.Narita T, Nakane S, Nagaishi A, Minami N, Niino M, Kawaguchi N, Murai H, Kira JI, Shimizu J, Iwasa K, Yoshikawa H, Hatanaka Y, Sonoo M, Shimizu Y, Matsuo H.Immunotherapy for ocular myasthenia gravis: an observational study in Japan.Ther Adv Neurol Disord.;16:17562864231163819.2023 doi: 10.1177/17562864231163819. eCollection 2023.
49.Noguchi-Shinohara M, Hamaguchi T, Sakai K, Komatsu J, Iwasa K, Horimoto M, Nakamura H, Yamada M, Ono K.Effects of Melissa officinalis Extract Containing Rosmarinic Acid on Cognition in Older Adults Without Dementia: A Randomized Controlled Trial.J Alzheimers Dis.;91(2):805-814.2023doi: 10.3233/JAD-220953.
50.Hirai T, Wang W, Murono N, Iwasa K, Inoue M.Potential role of Akt in the regulation of fibroblast growth factor 21 by berberine.J Nat Med.;78(1):169-179.2024 doi: 10.1007/s11418-023-01755-1.
[邦文原著]
1. 岩佐和夫：重症筋無力症における抗リアノジン受容体抗体について 金沢大学十全医学会雑誌 106:465-472，1997
2. 南部裕子，中出祐介，岩佐和夫，中田晶子，石田千穂，大場教子，山田正仁，和田隆志：脳波?筋電図の臨床 慢性炎症性脱髄性多発根神経炎(CIDP)における三叉神経体性感覚誘発電位(TSEP)の検討 臨床脳波 50:553-558，2008
3. 中田晶子, 南部裕子, 中出祐介, 高村 利治, 金田 礼三, 岩佐和夫, 酒井 佳夫, 和田 隆志：脳神経生理検査データネットワークシステム導入の効果 医学検査 59:873-876，2010
4. 篠原 もえ子, 柚木 颯偲, 堂本 千晶, 駒井清暢, 岩佐和夫, 中村 裕, 山田正仁： 地域における軽度認知障害及び認知症の早期発見?予防プロジェクト(なかじまプロジェクト)，老年期認知症研究会誌 19:98-100，2012
[欧文 症例報告]
1. Doi T, Iwasa K, Makifuchi T, Takamori M: White matter hyperintensities on MRI in a patient with corticobasal degeneration. Acta neuro logica Scandinavica 99:199-201. 1999
2. Ono K, Iwasa K, Shirasaki H, Takamori M: Sensorimotor polyneuropathy with 5-aminosalicylic acid: a case report. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 10:386-389. 2003
3. Machiya T, Yoshita M, Iwasa K, Yamada M. Primary spinal intramedullary lymphoma mimicking ependymoma. Neurology 68:872.2007
4. Shibata-Hamaguchi A, Samuraki M, Furui E, Iwasa K, Yoshikawa H, Hayashi S, Yamada M: Long-term effect of intravenous immunoglobulin on anti-MuSK antibody-positive myasthenia gravis. Acta neurologica Scandinavica 116:406-408. 2007
5. Hamaguchi A, Takahashi R, Iwasa K, Yamada M: Idiopathic sphenoidal defects detected by 3D computed tomography. Neurology 73:157-158. 2009
6. Hamaguchi A, Ishida C, Iwasa K, Abe A, Yamada M: Charcot-Marie-Tooth disease type 2D with a novel glycyl-tRNA synthetase gene GARS mutation. Journal of neurology 257:1202-1204. 2010
7. Ikeda T, Noto D, Noguchi-Shinohara M, Ono K, Takahashi K, Ishida C, Yoshita M, Kawaguchi M, Kawahara N, Iwasa K, Tomita K, Yamada M: CSF tau protein is a useful marker for effective treatment of superficial siderosis of the central nervous system: two case reports. Clinical neurology and neurosurgery 112:62-64. 2010
8. Furukawa Y, Iwasa K, Ono K, Yamada M: Fisher syndrome associated with immune thrombocytopenic purpura. Internal medicine Tokyo, Japan 50:631-633. 2011b
9. Furukawa Y, Hamaguchi A, Nozaki I, Iizuka T, Sasagawa T, Shima Y, Demura S, Murakami H, Kawahara N, Okuyama T, Iwasa K, Yamada M: Cervical pachymeningeal hypertrophy as the initial and cardinal manifestation of mucopolysaccharidosis type I in monozygotic twins with a novel mutation in the alpha-L-iduronidase gene. Journal of the neurological sciences 302:121-125. 2011
10. Takahashi R, Ikeda T, Hamaguchi A, Iwasa K, Yamada M: Coenzyme Q10 therapy in hereditary motor sensory neuropathy type VI with novel mitofusin 2 mutation. Internal medicine 51:791-793. 2012
11. Komatsu J, Iwasa K, Yanase D, Yamada M. Inclusion body myopathy with Paget disease of the bone and frontotemporal dementia associated with a novel G156S mutation in the VCP gene. Muscle Nerve 48:995-996. 2013
12. Iwasa K, Shima K, Komai K, Nishida Y, Yokota T, Yamada M. Retinitis pigmentosa and macular degeneration in a patient with ataxia with isolated vitamin E deficiency with a novel c.717 del C mutation in the TTPA gene. J Neurol Sci. 345(1-2):228-30.2014
13. Komatsu J, Sakai K, Hamaguchi T, Sugiyama Y, Iwasa K, Yamada M. Creutzfeldt-Jakob disease associated with a V203I homozygous mutation in the prion protein gene. Prion. 2014;8(5):336-8.
14. Hayashi K, Iwasa K, Morinaga A, Ono K, Yamada M. Exacerbation of myasthenia gravis by intravenous peramivir. Muscle Nerve. 2015;51(6):935-6.
15. Shima K, Iwasa K, Yoshita M, Yamada M. Vernet’s syndrome induced by internal jugular vein thrombosis. J Neurol Neurosurg Psychiatry. 2016；87：1252-1253
16. Komatsu J, Sakai K, Nakada M, Iwasa K, Yamada M. Long spinal cord lesions in a patient with pathologically proven multiple sclerosis. J Clin Neurosci. 2017;42:106-108.
17. Nakano H, Sakai K, Iwasa K, Yamada M. Cervical Flexion Myelopathy Eleven Years after a Cervical Spinal Cord Injury. Intern Med. 2017;56(16):2213-2215.
18. Muramatsu D, Yamaguchi H, Iwasa K, Yamada M. Cerebellar Hyperintensity Lesions on Diffusion-weighted MRI in MELAS. Intern Med. 2019. in press doi: 10.2169/internalmedicine.2190-18.
19.Hikishima S, Sakai K, Akagi A, Yamaguchi H, Shibata S, Hayashi K, Nakano H, Kanemoto M, Usui Y, Taniguchi Y, Komatsu J, Nakamura-Shindo K, Nozaki I, Hamaguchi T, Ono K, Iwasa K, Yamada M.: Deterioration after liver transplantation and transthyretin stabilizer administration in a patient with ATTRv amyloidosis with Leu58Arg (p.Leu78Arg) TTR variant. Internal Medicine, 61(15), 2347-2351, 2022.1
20.Nozaki I, Hashiguchi A, Takashima H, Yamashita Y, Higashide T, Iwasa K, Ono K.Charcot-Marie-Tooth Disease with a Novel Variant in Gap Junction Protein Beta 1 Presenting with Visual Field Defects.Intern Med.;62(20):3033-3036.2023 doi: 10.2169/internalmedicine.1403-22. Epub 2023 Feb 15.
[邦文 症例報告]
1. 坂尻顕一、岩佐和夫、沖野惣一、高守正治，声帯麻痺を伴った常染色体優性遺伝成人発症の脊髄筋萎縮症の一例 臨床神経学 40:712-6，2000
[邦文総説]
1. 岩佐和夫, 駒井清暢, 安川 善博, 高守正治：【分子筋肉病学】 自己免疫筋肉病 神経筋接合部疾患 電位依存性カルシウムチャネル(VGCC)の分子構造,機能とLambert-Eaton筋無力症候群(LEMS)の分子免疫学 日本臨床 55:3322-3330，1997
2. 高守正治, 駒井清暢, 岩佐和夫, 他；【分子筋肉病学】 自己免疫筋肉病 神経筋接合部疾患 アセチルコリン受容体(AChR)の分子生物学と重症筋無力症(MG)の分子免疫学的研究 日本臨床 55:3315-3321，1997
3. 高守正治, 岩佐和夫, 駒井清暢, 他：【イオンチャンネルと神経筋疾患】 Lambert-Eaton筋無力症候群と重症筋無力症 脳と神経 49:1089-1100，1997
4. 岩佐和夫：【神経?筋疾患とチャネロパチー】 重症筋無力症とカルシウム遊離チャネル(リアノジン受容体) 脳波と筋電図 26:79，1998
5. 駒井清暢、岩佐和夫、高守正治，傍腫瘍性症候群ーランバート?イートン筋無力症候群 カルシウムチャネルの分子構造と免疫 日本内科学会雑誌 87:678-684,1998
6. 駒井清暢, 岩佐和夫, 高守正治：【免疫性神経疾患】 傍腫瘍性神経症候群 Lambert-Eaton筋無力症候群 カルシウムチャネル分子構造と免疫 日本内科学会雑誌 87:678-684，1998
7. 高守正治, 駒井清暢, 岩佐和夫：自己免疫性カルシウムチャネル病としての筋無力症候群 生体の科学 50:329-336，1999
8. 岩佐和夫, 浅賀 知也, 高守正治：【免疫性神経疾患】 重症筋無力症における抗リアノジン受容体抗体と胸腺 日本内科学会雑誌 87:655-663，1998
9. 岩佐和夫, 山田正仁：【内科 この1年の進歩】 末梢神経?筋疾患 内科 90:1054-1061，2002
10. 岩佐和夫, 山田正仁：【わかりやすい免疫疾患】 免疫と病態 神経疾患 重症筋無力症 日本医師会雑誌 134:S271-S274，2005
11. 丸田高広, 吉川弘明, 岩佐和夫, 山田正仁：筋無力症関連自己抗体測定の現状と展望 神経免疫学 14:157-161，2006
12. 岩佐和夫：【新?図解救急?応急処置ガイド 救急?応急時に必ず役立つ基本手技と処置のすべて】 救急?応急処置の実際 救急疾患の病態の診断と救急処置 重症筋無力症性クリーゼ Medical Practice 25:832-837，2008
13. 岩佐和夫：神経筋接合部自己免疫疾患の病態に迫る 金沢大学十全医学会雑誌 117:14-17，2008
14. 岩佐和夫：【神経救急 見落しがちな神経疾患を中心に】 末梢神経?筋疾患の救急 重症筋無力症 Clinical Neuroscience 27:907-909，2009
15. 岩佐和夫：三訂脊髄小脳変性症のすべて 多系統萎縮症の最新の治療情報 難病と在宅ケア 16:49-51，2010
16. 岩佐和夫：【救急薬剤プラクティカルガイド】 疾患別救急薬剤ベストプラクティス 神経?筋?皮膚疾患 重症筋無力症クリーゼ 救急医学 35:1423-1426，2011
17. 岩佐和夫, 山田正仁：【ここまでわかった自己免疫疾患】 各論 そのほかの自己免疫疾患 重症筋無力症 臨床検査 55:1234-1240，2011
18. 吉川弘明, 岩佐和夫, 高守正治：【神経筋接合部 基礎から臨床まで】 重症筋無力症治療の現状と展望 胸腺手術の観点から BRAIN and NERVE: 神経研究の進歩 63:729-736，2011
19. 岩佐和夫：胸腺摘出術の適応、周術期、術式 Clinical Neuroscience 32：1040-1043、2014
20. 岩佐和夫：副腎脂質ステロイド、鎮痛薬によって誘発される認知症?認知障害 医薬ジャーナル 52（11）：101—104、2016
21. 岩佐和夫、山田正仁：意識障害を来す疾患の診療 脳炎 臨床と研究 94(9):1087-1092,2017
22. 岩佐和夫：感染症と重症筋無力症 Neuroinfection(神経感染症) 22（1）：40-43、2017
23. 岩佐和夫、山田正仁：よくわかる腫瘍随伴症候群—産婦人科医が学ぶべき諸疾患。2.亜急性小脳変性症 産科と婦人科 85(10)：1160-1165,2018
24. 岩佐和夫：筋骨格系と小胞体ストレス 重症筋無力症の骨格筋における小胞体ストレス応答 The Bone 32（2）：79-83,2018
[その他]
1. Yoshikawa H, Satoh K, Iwasa K, Takamori M: In vitro production of antiacetylcholine receptor antibody and IgG by peripheral blood lymphocytes of patients with myasthenia gravis. Annals of the New York Academy of Sciences 841:351-354. 1998
2. Takamori M, Iwasa K, Komai K: Antigenic sites of the voltage-gated calcium channel in Lambert-Eaton myasthenic syndrome. Annals of the New York Academy of Sciences 841:625-635. 1998
3. Iwasa K, Komai K, Asaka T, Nitta E, Takamori M: Motor dysfunction and autoantibodies in spontaneous thymoma buffalo/Mna rats. Annals of the New York Academy of Sciences 841:542-545. 1998
4. Iwasa K, Pinto A, Vincent A, Lang B: LEMS IgG binds to extracellular determinants on N-type voltage-gated calcium channels, but does not reduce VGCC expression. Annals of the New York Academy of Sciences 998:196-199. 2003
